--- title: Pharmacy and healthcare professionals nationwide recognize patient safety benefits of new consensus vancomycin dosing guidelines, but fewer than one in three plan to adopt them description: InsightRX's survey spotlights multiple benefits and key barriers to adoption of the first new consensus vancomycin dosing guidelines in more than a decade. image: https://blog.insight-rx.com/hubfs/5f0dd312a3d8ef202c170983_5f04fc39057f361381346416_-1.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Press Releases # Pharmacy and healthcare professionals nationwide recognize patient safety benefits of new consensus vancomycin dosing guidelines, but fewer than one in three plan to adopt them - Published July 8, 2020 By [InsightRX Communications](https://blog.insight-rx.com/press-releases/author/insightrx) ![](https://blog.insight-rx.com/hubfs/5f0dd312a3d8ef202c170983_5f04fc39057f361381346416_-1.png) SAN FRANCISCO, July 8, 2020 — For the first time since 2009, [consensus guidelines for vancomycin dosing](https://academic.oup.com/ajhp/article/77/11/835/5810200) were published in March 2020 by four pharmacy and infectious disease professional societies. The milestone marks a broad-based effort to reduce the incidence of acute kidney injury (AKI)—potentially fatal kidney failure or kidney damage—that can result from improper dosing of the antibiotic, as evidenced by a [recent retrospective study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579760/) found that 33% of 320 patients who received vancomycin sustained an AKI. The new guidelines call for moving away from an older method called trough-based dosing and adopting an area-under-the-curve (AUC) approach to estimating vancomycin exposure, preferentially recommending the use of Bayesian software to estimate AUC. Bayesian software uses patient data and laboratory results to predict a patient’s ability to absorb, process, and clear vancomycin from his or her system. According to the findings of a survey released today by InsightRX, 98% of pharmacy and healthcare professionals nationwide said they personally believe that the new vancomycin guidelines are important for patient safety. > “Vancomycin, like many other medications, requires tailored dosing regimens to maximize patient efficacy and safety,” said InsightRX CEO Sirj Goswami, PhD. “The antibiotic is highly effective in combating infections caused by staph bacteria, but its effects vary significantly from person to person.” In addition to patient safety, respondents to the InsightRX survey recognize both the cost and time savings that Bayesian software could present compared to manually estimating vancomycin exposure. More than half (54%) of respondents say that the Bayesian approach called for in the new guidelines can reduce overall costs and 45% say it can reduce lab expenditures. Nearly half (46%) say the Bayesian methodology can save pharmacist time compared to manual calculations. However, despite their appreciation for the benefits of the new vancomycin guidelines, the overwhelming majority of respondents have not yet adopted them. 86% of respondents still use trough-based dosing, which the new consensus guidelines recommend be discontinued. In addition, less than a third (31%) of respondents plan to adopt the new recommendations, while 60% are uncertain whether they will do so. Not having budgeted for Bayesian software, as well as being content with current vancomycin dosing methods, are the top two reasons for not shifting to AUC-guided dosing. > “Respondents are nearly unanimous in their personal belief that the new consensus guidelines are important for patient safety,” said Goswami. “However, their opinions are not translating to the adoption of an AUC-guided method in their own facilities.” Other findings of the InsightRX survey include: - **Dosing drugs with narrow therapeutic windows, like vancomycin, is challenging.** Respondents report significant challenges with existing dosing of vancomycin. Under- or over-dosing vancomycin (76%) and AKIs (62%) were listed as the top issues encountered when managing vancomycin therapy. - **Existing, trough-based vancomycin dosing relies heavily on professional judgment and manual tools rather than software.** While the updated guidelines recommend automation to address several issues with the current approaches to determining therapeutic vancomycin dosing, estimation based on professional judgement (55%) and manual calculation methods (49%) are currently the most prevalent approaches for adjusting vancomycin dose based on drug levels. - **AKIs are an industry problem, but not a hospital or health system priority.** While respondents agree that AKIs are an industry problem, most report it is not a problem in their hospital and is low on the priority list. 59% of respondents say that vancomycin-induced AKIs are not a problem in their hospitals, and AKIs ranked lowest among pharmacy challenges (8%) they face. About the Survey InsightRX commissioned an online survey of 126 healthcare professionals working in pharmacy and related roles in hospitals and health systems across the U.S. to assess their attitudes and behaviors regarding the newly released vancomycin dosing guidelines and related precision dosing topics. Conducted in April 2020, the survey has a margin of error of +/- 9%. [vancomycin](https://blog.insight-rx.com/press-releases/tag/vancomycin) [infectious diseases](https://blog.insight-rx.com/press-releases/tag/infectious-diseases) [MIPD](https://blog.insight-rx.com/press-releases/tag/mipd) [clinical evidence](https://blog.insight-rx.com/press-releases/tag/clinical-evidence) #### On this page… **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Press Releases Oct 28, 2025 The Christ Hospital Health Network Pharmacy Uses New Technology to Better Serve Patients](https://blog.insight-rx.com/press-releases/christ-hospital-pharmacy-technology-improves-patient-care) [Press Releases Mar 13, 2019 InsightRX And Children's Hospital Los Angeles (CHLA) To Partner On Precision Dosing](https://blog.insight-rx.com/press-releases/chla-bestdose-partners-precision-dosing) [Press Releases Jun 13, 2024 Northern Arizona Healthcare (NAH) Partners with InsightRX on the First Commercial Precision Dosing Model For Heparin](https://blog.insight-rx.com/press-releases/northern-arizona-healthcare-insightrx-precision-dosing-model-heparin) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "InsightRX Communications", "url" : "https://blog.insight-rx.com/press-releases/author/insightrx" }, "dateModified" : "2025-12-15T00:10:47.537Z", "datePublished" : "2020-07-08T23:33:00.000Z", "headline" : "Pharmacy and healthcare professionals nationwide recognize patient safety benefits of new consensus vancomycin dosing guidelines, but fewer than one in three plan to adopt them", "image" : [ "https://blog.insight-rx.com/hubfs/5f0dd312a3d8ef202c170983_5f04fc39057f361381346416_-1.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/press-releases/pharmacy-healthcare-professionals-recognize-patient-safety-benefits-vancomycin-dosing-guidelines-plan-adopt", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```